{"certainAgreement":{"piSponsorEmployee":true},"limitationsAndCaveats":{"description":"Study was discontinued due to FDA recommendations of the potential toxities of the combination of nivolumab with an immunemodulator(lenalidomide, pomalidomde)"},"pointOfContact":{"email":"Yvonne.Efebera@osumc.edu","organization":"The Ohio State University Comprehensive Cancer Center","phone":"614-293-7243","phoneExt":"1278","title":"Dr. Yvonne Efebera"}}